19 completed, 12 recruiting, 4 terminated, 3 active not recruiting. 13 Phase 2, 10 Phase 3, 2 Not applicable, 2 Phase 4, 1 Phase 1.
Follow Atypical Hemolytic Uremic Syndrome: new trials by email Literature Review of Atypical Hemolytic Uremic Syndrome trials Research Report on Atypical Hemolytic Uremic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| Ravulizumab Outcomes in Polish Patients With aHUS Ravulizumab - Atypical Hemolytic Uremic Syndrome | Recruiting | AstraZeneca | 80 | 2026-06-24 | 2026-09-15 | |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS Ravulizumab - aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2025-12-19 | 2026-04-20 |
| The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt Atypical Hemolytic Uremic Syndrome | Completed | AstraZeneca | 200 | 2025-10-13 | 2026-08-18 | |
| Study of Ultomiris® (Ravulizumab) Safety in Pregnancy Ultomiris - Ultomiris-exposed Pregnant/ Postpartum, Pregnancy | Recruiting | Alexion Pharmaceuticals, Inc. | 75 | 2024-12-16 | 2026-04-16 | |
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Iptcaopan 200 mg - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 65 | 2024-05-08 | 2026-06-04 |
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-02-28 | 2026-04-29 |
| Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases Skin biopsy - Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis | Not applicable | Recruiting | Mario Negri Institute for Pharmacological Research | 105 | 2024-02-21 | 2026-03-23 |
| A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients Atypical Hemolytic Uremic Syndrome(aHUS) | Active not recruiting | AstraZeneca | 367 | 2024-01-15 | 2026-10-26 | |
| Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome Soliris®, Renin angiotensin system blockers - Hypertensive Emergency-associated Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 66 | 2023-11-09 | 2024-01-05 |
| Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy Blood sampling and urine analysis - Atypical Hemolytic Uremic Syndrome | Not applicable | Recruiting | Mario Negri Institute for Pharmacological Research | 112 | 2023-05-03 | 2025-09-29 |
| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 34 | 2022-01-17 | 2026-08-07 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | Hoffmann-La Roche | 41 | 2021-11-17 | 2026-10-01 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | Hoffmann-La Roche | 83 | 2021-10-22 | 2026-10-30 |
| Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) Spacing of Eculizumab infusions - Hemolytic-Uremic Syndrome, Atypical | Phase 3 | Completed | University Hospital, Tours | 40 | 2021-10-20 | 2025-03-25 |
| Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical | Recruiting | Maastricht University Medical Center | 42 | 2021-08-11 | 2025-10-01 | |
| Eculizumab to Cemdisiran Switch in aHUS cemdisiran, Placebos - Atypical Hemolytic Uremic Syndrome | Phase 2 | Withdrawn | Mario Negri Institute for Pharmacological Research | 2021-01-01 | 2021-03-10 | |
| Observational Study of Elizaria® in aHUS Patients Elizaria® - Atypical Hemolytic Uremic Syndrome, aHUS | Completed | AO GENERIUM | 50 | 2019-12-19 | 2022-08-04 | |
| TTP and aHUS in Complicated Pregnancies ADAMTS 13, complement and angiogenic biomarkers - Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome | Unknown | University College, London | 150 | 2018-09-21 | 2018-09-25 | |
| Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Eculizumab - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 23 | 2018-08-03 | 2023-09-21 |
Showing 20 of 45. Sign in to see all of them.
Thrombotic Microangiopathies (13) · Glomerulonephritis, Membranoproliferative (3) · Hemolytic-Uremic Syndrome (3) · Kidney Diseases (3) · Thrombocytopenia (3) · Anemia, Hemolytic (2) · Cystinosis (2) · Denys-Drash Syndrome (2) · Glomerulonephritis, IGA (2) · Hemolysis (2) · Myasthenia Gravis (2) · Oculocerebrorenal Syndrome (2) · Polycystic Kidney, Autosomal Dominant (2) · Purpura, Thrombotic Thrombocytopenic (2)
Cytopenia (45) · Female Urogenital Diseases (45) · Female Urogenital Diseases and Pregnancy Complications (45) · Hemic and Lymphatic Diseases (45) · Male Urogenital Diseases (45) · Urogenital Diseases (45) · Anemia (44) · Blood Platelet Disorders (44) · Hematologic Diseases (44) · Uremia (44) · Urologic Diseases (44) · Anemia, Hemolytic (43) · Hemolytic-Uremic Syndrome (42) · Kidney Diseases (42) · Thrombocytopenia (42)
eculizumab (12) · ravulizumab (5) · narsoplimab (3) · avacopan (2) · iptacopan (2) · Blood Specimen Collection (1) · Celecoxib (1) · Itraconazole (1) · Midazolam (1) · Rifampin (1) · Urinalysis (1)
Alexion Pharmaceuticals, Inc. (16) · Mario Negri Institute for Pharmacological Research (4) · AstraZeneca (3) · Novartis Pharmaceuticals (3) · Hoffmann-La Roche (2) · Omeros Corporation (2) · AO GENERIUM (1) · Alnylam Pharmaceuticals (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Children's Hospital Medical Center, Cincinnati (1) · Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia (1) · Maastricht University Medical Center (1) · Michal Nowicki (1) · Nantes University Hospital (1)
United States (20) · France (17) · Italy (16) · Germany (15) · United Kingdom (15) · Canada (10) · Belgium (9) · Japan (9) · Spain (7) · Australia (6) · China (6) · Netherlands (6) · Poland (6) · Austria (5) · South Korea (5)
Amy Schmidt, MD PhD (1) · Giuseppe Remuzzi, MD (1) · Jose A Rojas, MD. Msc (1) · Marina Noris, PhD (1) · Michal Nowicki, MD, PhD (1) · Nader Najafian, MD (1) · Nuria Saval (1) · Oksana A. Markova, MD (1) · Pieter van Paassen, MD, PhD (1) · Sonata Jodele, MD (1) · Sydney Williams (1)
PMID 33783815, PMID 23738544, PMID 21877169, PMID 24360866, PMID 24843058, PMID 25833956, PMID 26654630, PMID 27871301, PMID 30971227, PMID 32299680, PMID 33048203, PMID 33270832, PMID 33407224, PMID 34169200, PMID 34852172, PMID 35439028, PMID 36152218, PMID 36329366, PMID 37946262, PMID 39105067, PMID 39468592, PMID 40875209, PMID 42853533
2014 (2), 2016 (2), 2023 (2), 2015 (1), 2018 (1)